Allspring Global Investments
IMRX icon

Allspring Global Investments’s Immuneering IMRX Stock Holding History

Allspring Global Investments’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,249
Closed -$53K – 2802
2022
Q1 		$53K Sell
8,249
-979
-11% -$9.4K ﹤0.01% 2840
2021
Q4 		$149K Buy
+9,228
New +$225K ﹤0.01% 2699

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments's IMRX Position: Q2 2022 in Review

Allspring Global Investments sold out of Immuneering (IMRX) in Q2 2022, closing a stake of 8,249 shares — an estimated $53K sold.

Allspring Global Investments first reported a position in IMRX in Q4 2021 and held it in 2 quarters. The position peaked at $149K in Q4 2021. 37 funds tracked by Wall St. Rank hold IMRX as of Q2 2022.

  • Allspring Global Investments reported no remaining Immuneering position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 8,249 Immuneering shares in Q2 2022, an estimated $53K.
  • Allspring Global Investments first reported a position in Immuneering in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Immuneering position peaked at $149K in Q4 2021.
  • 37 funds tracked by Wall St. Rank held Immuneering as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.